Lotus Pharmaceutical (美時) announced on the 21st significant progress in its Vietnamese portfolio acquisition. Following an asset purchase agreement signed in June 2025, the company has completed the closing conditions for four out of five acquired drug products: Betahema, Folinato, Carmotop, and Espacox. Commercial sales are expected to begin in Q1 2026.
Read more
